Document is current
Any future updates will be listed below
-
Authors
Johns, Ieuan
Moschonas, Konstantinos E
Medina, Jesús
Ossei-Gerning, Nicholas
Kassianos, George
Halcox, Julian P
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00882336 at ClinicalTrials.govnct00882336 at ClinicalTrials.govDocuments that mention this clinical trial
Risk classification in primary prevention of CVD according to QRISK2 and JBS3 ‘heart age’, and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study
https://doi.org/10.1136/openhrt-2018-000849
nct00882336 at ClinicalTrials.govDocuments that mention this clinical trial
Risk classification in primary prevention of CVD according to QRISK2 and JBS3 ‘heart age’, and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study
https://doi.org/10.1136/openhrt-2018-000849
Documents that mention this clinical trial
Risk classification in primary prevention of CVD according to QRISK2 and JBS3 ‘heart age’, and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study
https://doi.org/10.1136/openhrt-2018-000849
-
Funding
Funding for this research was provided by:
AstraZeneca
